South Wales based BBI develops and manufactures raw materials and finished test products for the in-vitro diagnostics market with manufacturing sites in five different countries, spanning four continents.
Dr. Mario Gualano, chief executive of BBI Group, said: “BBI are delighted to have been appointed to lead the manufacture of Avacta’s rapid Coronavirus antigen test and to be able to further extend our lateral flow expertise to addressing the global challenges presented by COVID-19.
“Our ability to respond rapidly to Avacta’s needs is testament to our team’s diagnostic expertise and the supporting manufacturing and quality systems we have implemented at our ISO13485 accredited facility.”
Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.